Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.54 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.51 |
| ▸ | FEN1 | P39748 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12907240 | 0.80 | JAK2 (0.63) | JAK2JAK1TYK2JAK3ALOX5AP | |
| SCHEMBL31240788 | 0.78 | JAK2 (0.54) | JAK2JAK1TYK2JAK3ALOX5AP | |
| SCHEMBL15639917 | 0.76 | JAK2 (0.49) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL1509530 | 0.76 | ALOX5AP (0.55) | LOXL2ALOX5APFEN1BTKMETAP2 | |
| SCHEMBL2660051 | 0.74 | JAK2 (0.55) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL4540461 | 0.74 | DYRK1B (0.55) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL15639843 | 0.73 | JAK2 (0.58) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL12907168 | 0.73 | PRKAG1 (0.68) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL558935 | 0.73 | ALOX5AP (0.55) | LOXL2ALOX5APFEN1GSK3BBTK | |
| SCHEMBL980447 | 0.73 | MAP4K4 (0.63) | LOXL2ALOX5APFEN1BTKDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| CN-101790526-A | 5-heteroaryl substituted indazoles as kinase inhibitors | ABBOTT GMBH & CO KG | 2010-07-28 | — | — | CN | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | JAK2 102/4885JAK1 73/4885TYK2 153/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | JAK2 102/4885JAK1 73/4885TYK2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.